COMMUNIQUÉS West-GlobeNewswire

-
Dr. Anosh Ahmed Foundation Launches Chicago-Based Initiative to Support Families of Fallen FBI Agents and Law Enforcement Officers
14/07/2025 -
Positive Response Fuels New Efforts by Dr. Anosh Ahmed and the Anosh Inc. Foundation to Support Families of Fallen Officers and FBI Agents
14/07/2025 -
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
14/07/2025 -
Ascentage Pharma Announces Proposed Top-Up Placement
14/07/2025 -
Anavar for Women: Exploring the Rise of Anvarol Performance Supplement Among Female Bodybuilders and Athletes From CrazyBulk
14/07/2025 -
NTG Nordic Transport Group A/S - H1 2025 Conference Call
14/07/2025 -
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
14/07/2025 -
Menerals Launches in San Diego with Bold Mission to Restore Strength and Masculinity Through Real Nutrition
13/07/2025 -
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
13/07/2025 -
Fat Burner For Men Launched Over the Counter in USA – PhenQ Medically Accredited Thermogenic Fat Burning Supplement for Men
13/07/2025 -
MSP Recovery Law Firm Secures Major Legal Win for MSP Recovery as Maryland Supreme Court Upholds Validity of Medicare Recovery Assignments for MSP Recovery and Its Healthcare Clients, Paving the Way for Medicare Recovery Rights Being Pursued Against GEICO
12/07/2025 -
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
13/07/2025 -
Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
11/07/2025 -
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/07/2025 -
4DMT Announces New Employment Inducement Grants
11/07/2025 -
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
11/07/2025 -
Clarification on Leadership Announcement: Annette Slyman not to join Life Backup Plan as Chief Operating Officer
11/07/2025 -
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
11/07/2025 -
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/07/2025
Pages